When it comes to healthcare, access to affordable prescription medications is a critical concern. Both Australia and Canada pride themselves on their universal healthcare systems, but they handle prescription drug pricing in notably different ways. While both countries strive to make essential medications accessible, drug costs in Canada are generally higher and more inconsistent than those in Australia. This article explores why that is and how the two nations stack up in the ongoing battle to keep drug prices under control.
Australia: Centralized Pricing and the Power of the PBS
Australia has a significant advantage when it comes to controlling drug prices, thanks largely to the Pharmaceutical Benefits Scheme (PBS). This federal program allows the Australian government to:
- Negotiate directly with pharmaceutical manufacturers
- Establish a fixed price for medications listed on the PBS
- Subsidize most of the cost for consumers
As a result, patients only pay a modest out-of-pocket fee—around AUD $31.60 per prescription for general patients and AUD $7.70 for concession card holders as of 2025. Once individuals or families reach the PBS Safety Net threshold, their co-payments drop even further or are eliminated for the remainder of the year.
This system keeps drug prices stable, predictable, and significantly lower than in many other countries. Australia’s centralized approach gives it strong bargaining power, enabling better control over both patented and generic drug pricing.
Canada: A Fragmented System with Higher Costs
In contrast, Canada operates under a provincial and territorial system with no single national drug coverage plan for all citizens. The federal Patented Medicine Prices Review Board (PMPRB) does set maximum allowable prices for patented medications, but it does not negotiate directly with pharmaceutical companies or regulate generic drug prices.
Canadians typically access medications through:
- Provincial drug plans (primarily for seniors, low-income individuals, and those with chronic conditions)
- Employer-sponsored private insurance
- Out-of-pocket payments if no other coverage exists
This patchwork approach leads to variability in drug prices across the country. While the PMPRB ensures that Canada doesn’t pay excessively high international prices, many Canadians still pay more out-of-pocket than Australians for the same drugs. In some cases, medications that are affordable under Australia’s PBS can be up to 3–5 times more expensive in Canada without sufficient insurance.
Access and Equity: A Growing Gap
Australia’s centralized PBS ensures consistent access and affordability, while Canada’s system can result in gaps in care, especially for those without private insurance. This is one reason why millions of Canadians report skipping medications due to cost, a situation far less common in Australia.
Canada has long debated the implementation of a national pharmacare program, which could mirror Australia’s PBS. However, such reforms have faced political and logistical challenges.
Conclusion
Australia and Canada both aim to keep prescription drugs affordable, but Australia’s government-led negotiation and subsidy model clearly provides more consistent access at lower costs. Canada’s reliance on a fragmented mix of public and private plans results in higher prices and less equity. As drug costs continue to rise globally, Canada may need to look more closely at the Australian model to ensure that all citizens can access the medications they need—without financial strain.